Bone Solutions Inc. (BSI) announced today that it has received FDA 510(k) clearance for a proprietary bone void filler, OsteoCrete, which represents a critical milestone in the company’s efforts to establish a platform for its patented magnesium-based technology. According to the company, OsteoCrete exhibits compressive strength and expandability yielding a binding quality that surpasses calcium-based orthobiologics. The magnesium-based material is resorbable as it is replaced with bone during healing and it is injecatble and osteoconductive. Tom Lally, President of BSI said in a release that the "magnesium-based technology along with other ingredients provides significant compressive strength and possesses Ph-neutral qualities that make it ideal as a delivery system for possible future applications.” The OsteoCrete Bone Void Filler device uses a similar material composite noted in the patent that the FDA cleared for long-bone and pelvis applications.